TEVA PHARMACEUTICAL FIN LLC's ticker is and the CUSIP is 88163VAE9. A total of 58 filers reported holding TEVA PHARMACEUTICAL FIN LLC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $740,000 | -2.4% | 8,000 | 0.0% | 0.09% | +31.3% |
Q4 2019 | $758,000 | +4.7% | 8,000 | 0.0% | 0.07% | -5.6% |
Q3 2019 | $724,000 | -1.1% | 8,000 | 0.0% | 0.07% | -4.1% |
Q2 2019 | $732,000 | -0.8% | 8,000 | 0.0% | 0.07% | -6.3% |
Q1 2019 | $738,000 | +2.2% | 8,000 | 0.0% | 0.08% | -14.1% |
Q4 2018 | $722,000 | -3.5% | 8,000 | 0.0% | 0.09% | +8.2% |
Q3 2018 | $748,000 | +0.8% | 8,000 | 0.0% | 0.08% | -7.6% |
Q2 2018 | $742,000 | +5.8% | 8,000 | 0.0% | 0.09% | 0.0% |
Q1 2018 | $701,000 | -0.1% | 8,000 | 0.0% | 0.09% | +7.0% |
Q4 2017 | $702,000 | -2.6% | 8,000 | 0.0% | 0.09% | -8.5% |
Q3 2017 | $721,000 | -16.0% | 8,000 | 0.0% | 0.09% | -15.3% |
Q2 2017 | $858,000 | -0.1% | 8,000 | 0.0% | 0.11% | -4.3% |
Q1 2017 | $859,000 | -1.9% | 8,000 | 0.0% | 0.12% | -10.1% |
Q4 2016 | $876,000 | -8.3% | 8,000 | 0.0% | 0.13% | -9.2% |
Q3 2016 | $955,000 | -4.8% | 8,000 | 0.0% | 0.14% | -13.4% |
Q2 2016 | $1,003,000 | -3.7% | 8,000 | 0.0% | 0.16% | -9.4% |
Q1 2016 | $1,041,000 | – | 8,000 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Southpaw Asset Management LP | 20,000,000 | $17,675,000 | 25.38% |
INCOME RESEARCH & MANAGEMENT | 23,109,000 | $20,278,000 | 5.29% |
Fore Capital, LLC | 5,000,000 | $4,430,000 | 1.71% |
RIVERHEAD CAPITAL MANAGEMENT LLC | 20,000,000 | $17,603,000 | 0.74% |
ARISTEIA CAPITAL, L.L.C. | 18,500,000 | $16,361,000 | 0.70% |
ZAZOVE ASSOCIATES LLC | 11,153,000 | $9,843,000 | 0.58% |
BASSO CAPITAL MANAGEMENT, L.P. | 3,600,000 | $3,182,000 | 0.52% |
CSS LLC/IL | 10,450,000 | $9,240,000 | 0.45% |
Lombard Odier Asset Management (Europe) Ltd | 7,950,000 | $7,038,000 | 0.44% |
Wellesley Asset Management | 6,740 | $5,948,000 | 0.31% |